Back to News
Mergers & Acquisitions

Drinks With The Deal: Sullivan & Cromwell’s Frank Aquila

|
Published: January 22nd, 2021
Sullivan’s head of M&A talks to The Deal's David Marcus about his recent work for Tiffany’s, Novartis and Amgen, the challenges consumer goods companies face, and his favorite bars in Hong Kong, Tokyo and New York.

Last fall’s sale of Tiffany’s Inc. (TIF) was perhaps the most-widely covered M&A transaction of 2019, as media of all sorts covered LVMH Moet Hennessy Louis Vuitton SE’s hostile bid for the jewelry retailer and its ultimately success deal to sell  to the luxury goods company for $16.2 billion.

But Frank Aquila, the Sullivan & Cromwell LLP partner who advised the target, told its directors to ignore the coverage and focus on achieving the best result for the company, as he discusses with The Deal’s David Marcus on the latest Drinks With The Deal podcast.

Aquila also talks about his work on two other large pharma deals last year. Sullivan’s head of M&A advised longtime client AmGen Inc. (AMGN) on its purchase of Otezla, a treatment for psoriasis and psoriatic arthritis, for $13.4 billion from Celgene Corp. (CELG) as part of its sale to Bristol-Myers-Squibb Co. (BMY) and Novartis AG on its $9.7 billion purchase of Medicines Co.

Aquila has done work for many years for Diageo plc and Anheuser-Busch InBev SA/NV (BUD), which he represented last fall on its $221 million purchase of Craft Brew Alliance Inc., and discusses the changing market that consumer goods companies face.

A food and wine aficionado in his spare time, Aquila enjoys searching out distinctive spots around the globe, from Angel’s Share, Brandy Library and Don Angie in Manhattan to The Old Man in Hong Kong and Bar Orchard in Tokyo.

More podcasts from The Deal are available on iTunesSpotify and on TheDeal.com.

 

More From Mergers & Acquisitions

Mergers & Acquisitions

Drinks With The Deal Podcast: Paul Hastings' Steve Camahort

By David Marcus
|
Published: June 16th, 2022
On this week's Drinks With The Deal podcast, Steve Camahort, the chair of global M&A at Paul Hastings, discusses Elon Musk's bid for Twitter as well as the evolution of tech PE and the Bay Area legal market.